Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a biomarker of Acute kidney Injury (AKI) by Cátia Sofia Almeida Oliveira
2017/2018
Cátia Sofia Almeida Oliveira
Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
as a biomarker of Acute Kidney Injury (AKI) / 
Lipocalina associada à gelatinase neutrofílica como 
biomarcador da Lesão Renal Aguda
março, 2018
Mestrado Integrado em Medicina
Área: Nefrologia
Tipologia: Monografia
Trabalho efetuado sob a Orientação de:
Professor Doutor Luís Alexandre de Castilho Silva Coentrão
Trabalho organizado de acordo com as normas da revista:
Portuguese Journal of Nephrology and Hypertension
Cátia Sofia Almeida Oliveira
Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a biomarker
of Acute Kidney Injury (AKI) / Lipocalina associada à gelatinase
neutrofílica como biomarcador da Lesão Renal Aguda
março, 2018


4 
 
Agradecimentos  
 
Em primeiro lugar, à minha família, em especial aos meus pais, por sempre acreditarem 
em mim e apoiarem todas as minhas decisões. 
À minha prima Catarina, pela disponibilidade, apoio e ajuda na realização deste trabalho. 
Às minhas amigas, Ana Filipa e Ana Cláudia, por ouvirem as minhas preocupações e me 
apoiarem incondicionalmente. 
Por fim, mas com um papel essencial na realização deste trabalho, ao meu Orientador 
Prof. Dr. Luís Coentrão, pela sua capacidade de simplificar e clarificar os temas, bem 
como disponibilidade e apoio demonstrados.  
5 
 
Index 
 
Abstract ............................................................................................................................. 6 
Resumo ............................................................................................................................. 7 
Introduction ...................................................................................................................... 8 
Methods .......................................................................................................................... 10 
The classic biomarkers of AKI ....................................................................................... 11 
Creatinine .................................................................................................................... 11 
The novel biomarkers of AKI ......................................................................................... 12 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) ............................................... 12 
Conclusion ...................................................................................................................... 16 
References ...................................................................................................................... 17 
Appendix ........................................................................................................................ 34 
Appendix I – Table I ................................................................................................... 34 
Appendix II – Table II ................................................................................................ 36 
Appendix III – Figure 1 .............................................................................................. 43 
Appendix IV – Table III ............................................................................................. 44 
Appendix V - Portuguese Journal of Nephrology and Hypertension: Instructions to 
Authors ........................................................................................................................ 45 
 
  
6 
 
Abstract 
 
Background: Acute kidney injury (AKI) is a condition associated with a high mortality 
and morbidity, affecting patients, daily. As a result, it is imperative to identify a suitable 
diagnostic biomarker, which can identify acute kidney injury, even at its earliest stages, 
thereby enabling prompt interventions and improving the patients’ clinical outcomes. 
However, because of its limitations, in the last few years, numerous studies have been 
carried out to identify new biomarkers that enable an earlier detection of acute kidney 
injury. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is one of the most promising 
biomarkers, particularly when considering the monitoring of AKI. 
Objective: To summarize the biological and physiological data of NGAL and to review 
clinical studies related to this biomarker. 
Methods: A literature review was undertaken focusing on new biomarkers used in the 
clinical diagnosis of AKI, especially NGAL. To achieve this, a MEDLINE search was 
undertaken using the terms “acute kidney injury (AKI)”, “biomarker” and “Neutrophil 
gelatinase-associated lipocalin (NGAL)”. The selected papers were published between 
January 2005 and July 2017 and included the above terms in the title and abstract. 
Results: 111 papers were analysed, showing that urinary and serum NGAL can predict 
AKI in several patient population groups (Area under the receiver operator characteristic 
curve (AUC) mean: 0.81), as well as the clinical outcomes of this condition, such as 
length of stay, worsening AKI, need for renal replacement therapy and mortality. 
Conclusions: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is the most widely 
studied novel biomarker. It demonstrates a high sensitivity and specificity for the 
diagnosis of acute kidney injury, as well as some prognostic information. 
  
Keywords: Acute kidney injury; Biomarkers; Neutrophil gelatinase-associated lipocalin. 
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Resumo 
 
Introdução: A lesão renal aguda é uma condição com elevada morbilidade e mortalidade, 
que afeta diariamente um grande número de doentes. Deste modo, torna-se imperativo a 
realização de um diagnóstico precoce, para a instituição de uma intervenção atempada, 
com vista à obtenção de melhores resultados clínicos. Contudo, dadas as suas limitações, 
nos últimos anos, vários estudos têm sido realizados no sentido de identificar novos 
biomarcadores que permitam a deteção precoce desta condição. O Lipocalina associada 
à gelatinase neutrofílica (NGAL) é um dos biomarcadores mais promissores, 
especialmente no que se refere à monitorização da lesão renal aguda. 
Objetivo: Resumir as características biológicas e fisiológicas do NGAL e fazer uma 
revisão dos ensaios clínicos relacionados com este biomarcador.  
Métodos: Realizou-se uma revisão da literatura, com enfoque nos biomarcadores 
utilizados para o diagnóstico de lesão renal aguda, especialmente, o NGAL. Com este 
intuito, efetuou-se uma pesquisa na MEDLINE usando os termos “acute kidney injury 
(AKI)”, “biomarker” e “Neutrophil gelatinase-associated lipocalin (NGAL)”. Os artigos 
publicados entre Janeiro de 2005 e Julho de 2007, cujos termos acima estavam incluídos 
no título e resumo, foram selecionados. 
Resultados: Foram analisados 111 estudos, que mostraram que o NGAL urinário e 
plasmático conseguem prever a ocorrência de Lesão Renal Aguda em diferentes 
populações (AUC média: 0.81), bem como resultados clínicos desta condição, como 
tempo de internamento, agravamento da lesão renal aguda, necessidade de terapia de 
substituição renal e mortalidade. 
Conclusões: O NGAL é um dos biomarcadores mais estudados, cujos resultados 
demonstraram uma grande sensibilidade e especificidade no diagnóstico da doença, bem 
como no seu prognóstico.  
 
Palavras-chave: Biomarcadores; Lesão renal aguda; Lipocalina associada à gelatinase 
neutrofílica.  
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Introduction 
 
Acute Kidney Injury (AKI) is characterised by the sudden reduction in kidney 
function which normally occurs within 24-48 hours. This can result in changes in the 
acid-base balance in addition to fluid and electrolyte levels.1  
AKI is a common presentation which can affect patients in different medical 
specialties. It is associated with significant morbidity and mortality2 including adverse 
clinical outcomes such as cardiovascular events3 and chronic kidney disease.4 
There are various causes of AKI which are generally divided into 3 categories: 
pre-renal, intrinsic and post-renal causes. Pre-renal causes are the commonest causes of 
AKI whereby a reduction in the Glomerular Filtration Rate (GFR) results in renal 
hypoperfusion because of a reduction in effective arterial pressure to the kidney. This is 
usually caused by some extrinsic event outside of the kidney which subsequently affects 
the arterial supply to the kidney. In this category, the renal parenchyma is not the primary 
source for the renal failure but rather, the compensatory mechanisms initiated because of 
these external pressures, results in AKI. This is important because the damage is 
potentially reversible. Intrinsic renal causes, however, are the result of specific renal 
diseases such as acute interstitial nephritis and acute glomerular nephritis. Post-renal 
causes are generally the result of obstruction affecting the urinary tract causing an 
obstructive nephropathy.5  
Unfortunately, for several years there has been no agreement on the precise 
clinical definition of AKI. This has meant that it is extremely difficult to compare studies 
or their outcomes.6 
Subsequently, in 2004, the Acute Dialysis Quality Initiative (ADQI) group 
established the first criteria for the diagnosis and classification of AKI called the Risk, 
Injury, Failure, Loss and End-stage Kidney (RIFLE) criteria. These criteria classified AKI 
into 3 severity groups (risk, injury and failure) according to either changes in serum 
creatinine (sCr) or urine output (UOP). The criteria also predicted one of 2 outcomes 
(Loss and End-stage Renal Disease) which was determined by the duration of kidney 
dysfunction.6 
The Acute Kidney Injury Network (AKIN) criteria was subsequently developed 
to improve several weaknesses of the RIFLE criteria. The AKIN criteria classified the 
injury into three stages and did not require a baseline sCr. Instead, it defined AKI by the 
increase in sCr of 0.3mg/dL or 1.5 times its initial recorded value.7 The specific time 
criteria proved to be a major flaw as some AKI can occur over periods longer than 48 
hours.8 
Most recently, the RIFLE and AKIN criteria were combined to form the Kidney 
Disease: Improving Global Outcomes (KIDGO) clinical practice guidelines which 
clinically defined AKI in one of three ways:  
1) An increase in sCr of 0.3mg/dL within 48 hours OR 
2) An increase in sCr of 1.5 times the base (or its first measurement) OR 
3) A UOP <0.5mL/kg/hr for 6 hours.1 
These most recent clinical guidelines were thought to be advantageous in that they 
took into account small changes in sCr, unlike the RIFLE criteria, and were not restricted 
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to a time period of 48 hours, as stipulated in the AKIN criteria.9 Nevertheless, the use of 
sCr as a biomarker for AKI also has certain limitations namely that sCr can be affected 
by other factors unrelated to renal function, the rise in sCr is a delayed response to the 
initial insult, and sCr provides no information related to the aetiology or the nature of the 
renal lesion. sCr is therefore purely a marker of function.10  
There is a consensus however, that it is important to accurately diagnose AKI 
early, preferably at its cellular stress stage before permanent damage occurs.11 This will 
enable the implementation of adequate therapeutics which will improve post-AKI 
outcomes.12 Therefore, there is a need to identify sensitive and specific biomarkers which 
can help to accurately diagnose AKI at the cellular stress stage.9 
The purpose of this paper is to summarise the biological and physiological data of 
the most widely studied biomarker Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
and review the clinical studies related to this biomarker.   
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Methods 
 
A literature review was undertaken focusing on novel biomarkers used in the 
clinical diagnosis of AKI, especially NGAL. To achieve this, a MEDLINE search was 
undertaken between April and August 2017 using the terms “acute kidney injury (AKI)”, 
“biomarker” and “Neutrophil gelatinase-associated lipocalin (NGAL)”. 
Initially, only literature review papers published between January 2013 and July 
2017 using the above terms (“acute kidney injury (AKI)” and “biomarker”) included in 
the title and abstract, were selected. This literature search was subsequently expanded, 
using the references included in the initially selected literature review papers.  
Subsequently, using the term “Neutrophil gelatinase-associated lipocalin 
(NGAL),” a second search was carried out with the aim of identifying clinical studies 
which evaluated the capacity for urinary and plasma NGAL to predict AKI in humans. 
Only publications between January 2005 and July 2017 were used. As described earlier, 
the title and subsequent review of the abstracts enabled the selection of the most 
appropriate publications. Only articles which focused on the following patient 
populations were selected:  
 patients undergoing cardiac surgery, with contrast-induced nephropathy 
(CIN),  
 admitted to the Intensive Care Unit (ICU),  
 burns,  
 after hematopoietic stem cell transplantation (HSCT),  
 with drug-induced nephrotoxicity,  
 admitted to the Emergency department (ED),  
 patients with hypoplastic left heart syndrome (HLHS), 
 after liver transplantation and  
 patients delay graft function (DGF) following kidney transplantation. 
111 clinical trials were selected for critical appraisal with the primary objective of 
identifying in each case, the following:  
 study type,  
 sample size,  
 population type,  
 clinical setting,  
 NGAL measurement,  
 method of detection,  
 AUC,  
 AKI definition and  
 prognostic outcome.  
Retrospectively, the mean and standard deviation of Area under the receiver 
operator characteristic curve (AUC) were calculated for all studies in addition to each 
clinical study.   
11 
 
The classic biomarkers of AKI 
 
Renal biomarkers identify whether renal function is normal or impaired.13 To fulfil 
this purpose, a good biomarker should have the following characteristics: 1) be easy and 
simple to measure, 2) be reliable and consistent in repetitive measurements, 3) be cost 
effective, 4) provide rapid results, 5) be able to identify source of the injury, 6) should 
differentiate between pre-renal azotemia and chronic kidney disease, 7) enable some 
estimate of the timing of onset, 8) indicate the severity of injury, 9) enable predictions of 
patient outcomes (recovery, dialysis and mortality)14, 10) enable monitoring of 
pharmacological responses to therapy.15  
The definition of AKI has traditionally been based on the measure of the sCr level. 
 
Creatinine 
 Creatinine is a 113 Da protein, formed from creatine in the muscles. In the kidney, 
it is freely filtered through the glomeruli and is neither absorbed nor metabolized. It is 
non-toxic and is not bound to any protein. These characteristics make it a practical 
indicator of GFR.16 
 The proximal tubules are responsible for approximately 10-20% of the excreted 
load. Therefore, taking this into account, if we use creatinine clearance as a measure of 
GFR, creatinine clearance will overestimate the GFR. This contribution can be as high as 
50% of the creatinine clearance when the glomerular filtration process may actually be 
reduced.16 
 However, the concentration of sCr is influenced by a lot of factors. There is also 
a non-linear inverse relationship between sCr and GFR (particularly in patients with near-
normal renal function), which means that it may not accurately reflect the degree of renal 
dysfunction.5 
 Many studies have therefore concluded that sCr is not an adequate marker of renal 
function. Other limitations of this marker are as follows: 
1) Muscle mass is affected by the age, sex, race and weight of the patient. This in 
turn will influence the production of sCr by the muscle. This variation therefore 
makes this a poor marker of renal function especially when trying to identify 
patients with AKI;   
2) The renal tubular epithelium also secretes creatinine; 
3) Severely ill patients generally are in a hypercatabolic state, which will alter the 
metabolism of creatinine in AKI; 
4) Patients with AKI require aggressive intravenous fluid administration which will 
likely cause dilution of creatinine; 
5) Some drugs may change the tubular secretion of creatinine; 
6) Creatinine levels are a late and indirect sign of damage to the kidney; 
7) The time frame of urine collection may not be practical or accurate.5,17 
Serum Creatinine could be considered a kidney function biomarker.5 However, 
because of its poor sensitivity and specificity, it is a poor predictor of kidney damage in 
AKI 18.  
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The novel biomarkers of AKI 
 
In view of the limitations associated with sCr as a AKI biomarker, in the last few 
years, there have been a lot of studies looking at a series of other molecules involved in 
the pathogenesis of AKI with a view to analysing their potential as biomarkers.19,20 
One of the most investigated biomarker is NGAL is described below.  
The characteristics of others promising AKI biomarkers are summarized in table 
I. 
 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
 Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a small protein 
(approximately 25 kDa in size), that belongs to the superfamily of the lipocalins. It was 
originally found in human neutrophils having been localized in their specific granules.21 
However, subsequent studies identified this protein in other immune cells and several 
tissues and organs (trachea, lung, stomach, liver, colon and kidney).22 
 NGAL exists in several formats including a 45 kDa homodimer which is produced 
by neutrophils. It also exists as a monomer and a 135 kDa heterodimer which are 
predominant forms produced by proximal tubular epithelial cells. The heterodimeric form 
is conjugated to gelatinase.23 
 NGAL has also been found to be produced primarily in the thick ascending loop 
of Henle and the intercalated cells of the collecting ducts24. It is freely filtered through 
the glomeruli due to its low molecular weight and positive charge. It is subsequently 
reabsorbed by the proximal tubule, where it is degraded by megalin and partly excreted 
in urine. Therefore, in healthy subjects, it is expressed in low constant levels, at a 
concentration of approximately 20 ng/mL, both in the serum and in the urine.14 
 However, NGAL production increases as we get older and is greater in the female 
population.25 
 Human (neonates, children and adults) and animal model studies shows that 
NGAL is upregulated and released into the plasma and the urine after an ischemic or toxic 
injury to the renal tubular cells.26 
 Following cellular damage, NGAL plays a role as a stimulator of epithelial growth 
by inducing the differentiation of kidney progenitor cells into tubular epithelial cells, 
thereby enhancing neutrophil apoptosis in renal tubular interstitial cells.27 This protein 
has a bacteriostatic function through its ability to sequester iron-siderophore complexes 
which prevents iron uptake by bacteria.28 
 Following an acute kidney injury event, there is decreased tubular reabsorption of 
the protein resulting in elevated urinary concentration levels.19 The levels of NGAL rise 
three hours after cellular damaged and its concentration peak is detectable approximately 
6-12 hours, according to the severity of injury. If the injury is severe, this elevation can 
persist up to 5 days.29,30 Subsequently, urine and plasma concentrations increase rapidly 
and proportionally to the duration and severity of the insult.31 
Some authors believe that the rise in urine NGAL can differentiate between 
intrinsic renal injury and hemodynamic alterations (volume depletion).32,33 
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Given the above features of NGAL, it has become the most extensively studied 
AKI biomarker20, with some studies looking at variations in several patient population 
groups (see Table II). It has been studied in the following scenarios as a predictor of AKI 
in neonates, children and adults undergoing cardiac surgery29-31,34-65; children and adults 
with contrast-induced nephropathy (CIN)66-77; critically ill patients admitted to the 
Intensive Care Unit (ICU)33,57,78-93; burn patients94-98; patients after hematopoietic stem 
cell transplantation (HSCT)99; patients with drug-induced nephrotoxicity100-104; patients 
admitted to the Emergency department (ED)32,33,105-111; patients with hypoplastic left heart 
syndrome (HLHS)112; patients after liver transplantation113-120 and patients with delay 
graft function (DGF) following kidney transplantation.121-141 
111 clinical trials [see Table II] who used NGAL as a predictive marker of AKI 
were critically appraised. Some trials only evaluated the performance of urinary NGAL 
(52 clinical trials), or serum NGAL (34 clinical trials), whilst the remainder analysed both 
serum and urinary NGAL (24 clinical trials) [see Table III]. The majority of the clinical 
trials were prospective, carried out primarily on patients following cardiac surgery 
followed by post-renal transplants, ICU admissions and Contrast-Induced Nephropathy 
(CIN) as illustrated in Figure 1.  
We can identify that many of these studies looking at NGAL in different 
population groups used very small sample sizes. Nevertheless, when comparing different 
studies looking at the same population groups, similar results were achieved.   
Conventional enzyme-linked immunosorbent assay (ELISA) was the principle 
method used to detect NGAL in these clinical trials in addition to chemiluminescent 
microparticle immunoassay (CMIA) in the case of urinary NGAL and the Triage Meter 
in the case of serum NGAL, amongst others.  
When analysing the performance of NGAL, we can verify the overall mean AUC 
from the different studies is 0.810 ± 0.13. In the case of urinary NGAL, the mean AUC 
is 0.817 ± 0.12 and in plasma NGAL, the mean AUC is 0.800 ± 0.14. However, some of 
the clinical trials used other statistical methods (such that AUC was not used) to estimate 
the performance of NGAL. If we compare the mean AUC obtained from the different 
populations studied [see Table III] we can verify that the results obtained are very similar.  
When analysing each different population group, patients who underwent cardiac 
surgery made up the greatest proportion of patients analysed in these clinical trials with a 
mean AUC of 0.807 ± 0.14. Over half of the clinical trials only analysed the performance 
of urinary NGAL. Despite some trials showing some good results, there were some 
clinical trials which concluded some limited diagnostic accuracy in predicting AKI (AUC 
≤ 0.700), regardless of whether urinary or plasma NGAL was analysed in adults.30,40,61,63 
On the other hand, in the trials involving children, results for plasma NGAL were similar 
to those described in the adult population (AUC < 0.600).53,65 In one trial looking at the 
performance of urinary NGAL in adults, an AUC result of 0.500 was obtained which 
suggests a limited capacity of NGAL to be used as a predictor of AKI.64 Nevertheless, 
this was one trial and there are other clinical trials which suggest otherwise.  
The measurements of NGAL in patients with delayed graft function (DGF) after 
a renal transplant was the second most common population group used in the clinical 
trials selected with a mean AUC of 0.843 ± 0.12, and as with the previous group, this was 
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made up largely by the analysis of urinary NGAL. In this population group, however there 
are also contradicting clinical trials. In the adult population, in 3 trials which analysed the 
performance of both biomarkers, one trial concluded that both biomarkers had a limited 
capacity to predict AKI.126 In another, urinary NGAL was not a good predictor of AKI 
unlike plasma NGAL which was more promising.134 In the third clinical trial, the opposite 
conclusion was reached in that the urinary NGAL showed more promising results in the 
prediction of AKI unlike the plasma NGAL which did not.133 In the children’s population 
groups, there was one study in which they evaluated both biomarkers which revealed that 
urinary NGAL is not a good predictor of AKI unlike plasma NGAL.130 Nevertheless, in 
studies which analysed both urinary NGAL and plasma NGAL in isolation, both 
biomarkers demonstrated good results.  
In patients admitted to the ICU, the mean AUC was 0.769 ± 0.15. There was a 
balanced number of trials that looked at urinary and/or plasma NGAL. In the adult 
population groups, only 3 trials were identified which showed some discrepancies. In 2 
of those studies, they concluded that urinary NGAL is a good predictor of AKI unlike 
plasma NGAL.80,85 The third trial showed that both urinary and plasma NGAL were poor 
biomarkers for AKI (AUC < 0.530).86 However, in the children’s population group, one 
study which looked at plasma NGAL, concluded that plasma NGAL was not a good 
biomarker for AKI.88 As previously mentioned, other studies included in this review had 
differing results and conclusions.  
In patients with CIN, the mean AUC was 0.796 ± 0.18 with studies looking at both 
biomarkers (urinary and plasma) showing some limitation in this role. One study recently 
published showed that urinary NGAL demonstrates no capacity as a predictor of AKI 
(AUC 0.510).71 
In patients who have undergone a liver transplant, the mean AUC was 0.794 ± 
0.07 with only one study looking at the performance of plasma NGAL showing some 
limitation in its diagnostic role in AKI.120  
In patients who have sustained burns, which represented the smallest number of 
clinical studies (only 5 identified), the mean AUC was 0.821 ± 0.14, whereby 2 articles 
which looked at plasma NGAL showed an AUC < 0.700.96,97 
In the remainder populations, patients admitted to the ED and drug-associated 
nephrotoxicity, the mean AUC was 0.850 ± 0.08 e 0.847 ± 0.04 respectively, such that all 
the studies analysed showed some superiority of both urinary and plasma NGAL in the 
diagnosis of AKI.  
Therefore, whilst most of studies show that NGAL is a good predictor of AKI, 
there are studies which show some discrepancies indicating that NGAL cannot have that 
function. On the other hand, in clinical studies looking at similar population groups and 
the performance of urinary and serum NGAL, these studies appear to indicate that one 
form of NGAL may be better than the other.    
In all these studies, AKI was defined using one of the recognised criteria for AKI, 
namely either RIFLE and/or AKIN. As previously mentioned, these classifications 
require the use of creatinine. Therefore, despite all the limitations associated with the use 
of creatinine, these criteria were used as the standard with which to compare the 
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performance of NGAL as a AKI biomarker. Unfortunately, there is no gold-standard in 
the diagnosis of AKI.  
The NGAL biomarker was also shown to predict the severity and duration of 
AKI37,92,105 as well as the clinical outcomes of this condition, such as length of 
stay30,35,37,42,50,65, worsening AKI32,37,92,93,142, renal recovery143, UCI admission33, 
nephrology consultation33, need for renal replacement therapy 
(RRT)32,33,37,65,72,77,81,89,92,93,96,105,122,142 and mortality.30,32,35,37,42,57,77,81,92,93,96,105,110 
Hasse et al.144 created “subclinical AKI” as a new category of patients that have 
risen urinary NGAL levels but a normal serum creatinine level, created “subclinical AKI” 
as a new category of patients that have risen urinary NGAL levels but a normal serum 
creatinine level, that is the presence of some renal damage without the loss of renal 
function simultaneously.  
In addition to this group, there exists another group which needs to be recognised, 
namely those patients in which there is a reduction in renal function in the absence of 
renal damage, for example pre-renal azotemia. In this case, there are raised levels of 
creatinine without an increase in the levels of the NGAL biomarker.145 This indicates that 
NGAL alone cannot be used to diagnose this conditions in the relevant patients.  
Many studies show that both urinary and plasma NGAL are good 
biomarkers146,147, however some authors have suggested that the elevation of urinary 
NGAL concentration is more specific than the elevation of serum concentration.146 
Plasma NGAL may be influenced by various factors, such as bacterial infections, 
systemic inflammation and malignancy.148 A venous blood sample is easy to obtain, 
although it is considered an invasive procedure.20  Urinary NGAL, however, is relatively 
unaffected by external factors, although if the patient is anuric, it may not possible to 
collect a urine sample to enable analysis.80   
Several clinical studies and reviews have concluded that both plasma and urinary 
NGAL levels increase much earlier and show better sensitivity than sCr, in the diagnosis 
and prognosis of AKI.29,35,146 
Compared with other novel biomarkers, NGAL can diagnose AKI earlier than 
serum Cystatin C (CysC)67, but predicts AKI much less effectively than Insulin-like 
Growth Factor-Binding Protein 7 (IGFBP7) and Tissue Inhibitor of Metalloproteinases-
2 (TIMP2).149 Moreover, the Kidney Injury Molecule 1 (KIM-1) is more specific than 
NGAL, but it is less sensitive.20  
To complete this work, it would be important to understand for each population 
used in the study of NGAL, what the cut-off values would be and the time period which 
would enable a better prediction of AKI, in addition to its performance when utilised in 
conjunction with other biomarkers.  
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Conclusion 
  
In the last few years, there has been much research to identify ways to improve 
the early diagnosis of AKI. A lot of work has looked into the pathophysiology of AKI to 
identify several biomarkers in a variety of different population groups with promising 
results.   
 NGAL is one of the most promising biomarkers particularly with regards to the 
monitoring of AKI following several studies in a variety of clinical settings. It is an 
excellent biomarker with a high sensitivity and specificity as well as the potential to 
predict a patient’s potential clinical outcome (recovery, dialysis and mortality). 
 However, there is evidence to suggest that it may be influenced by several 
interference factors and therefore may only be suitable to patient with fewer 
complications. 
 In view of this, it may not be possible to use a single biomarker, but rather combine 
the results of several biomarkers to enhance the diagnostic and prognostic predictions of 
patients with AKI.  
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Appendix 
Appendix I – Table I 
 
Biomarker Characteristics Mechanism 
of release 
Presence/levels in 
healthy individuals 
Source  Method of detection AKI predictor Advantages Limitations 
CysC Protease inhibitor 
produced in all 
nucleated cells. 
Freely filtered by the 
glomerulus, 
completely reabsorbed 
and degraded but not 
actively secreted150 
 
GFR 
reduction14 
Serum levels: yes151 Serum150 ELISA; 
nephelometric; 
Turbidometric assays14 
Burn patients152 
Adults35 and children53,153 
patients undergoing cardiac 
surgery 
Drug-induced nephrotoxicity154 
High sensitivity and 
specificity to GFR155 
In neonates, CysC is 
independent of 
maternal values156,157 
Lack of a standardized test 20  
CysC levels may be influenced by 
thyroid dysfunction, 
immunosuppressant use, systemic 
inflammatory response158 and 
smoking155 
NAG Enzyme produced by 
lysosomes of the renal 
proximal tubular 
cells159 
Cellular 
injury159 
Urinary levels: 15.1 
U/L160 
Urine159 ELISA; 
Spectrophotometric 
assay14 
Drug-induced nephrotoxicity154 
Critically ill patients admitted to 
the ICU160 
CIN161 
Useful, non-invasive, 
simple, inexpensive161 
NAG levels may be influenced by 
industrial solvents, heavy metals and 
disease states (rheumatoid arthritis, 
abnormal glucose tolerance, 
hyperthyroidism)20  
Urinary elevation may reflect 
increased lysosomal activity159  
KIM-1 Transmembrane 
glycoprotein of the 
renal proximal 
tubule162 
Ischemic or 
toxic injury162 
No162 Urine162/  
Serum163 
 
ELISA; 
immunoblotting14 
CIN164 
Adult patients undergoing 
cardiac surgery34,63 
Drugs-induced 
nephrotoxicity154  
Patients admitted to the ED105 
 
Non-invasive, not 
affected by the 
physicochemical 
properties of urine20  
High cost, poor availability165  
KIM-1 levels may be influenced by 
chronic proteinuria and 
inflammatory diseases166 
 
L-FABP Cytoplasmic protein of 
the renal proximal 
tubule167 
Ischemic167 or 
toxic injury168 
 
No13 Urine167 ELISA14 Drug-induced nephrotoxicity168 
Patients in septic shock169 
CIN170 
Adult171 and children172 patients 
undergoing cardiac surgery  
Critically ill patients admitted to 
the ICU173 
Patients admitted to the ED105 
 
 
 
 
      ______________ 
Urinary L-FABP elevation in 
patients with anaemia174 
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IL-18 Cytokine of the renal 
proximal tubule175 
Ischemic or 
toxic injury175 
Urinary levels: yes175 Urine175 ELISA14 Patients admitted to the ED105 
DGF following kidney 
transplantation121,175 
Adults30 and children65 patients 
undergoing cardiac surgery  
Critically ill patients admitted to 
the ICU176 
Detection is fast, 
reliable and 
inexpensive175 
IL-18 levels may be influenced by 
endotoxin, inflammation and 
immune factors177 
Serum IL-18 elevation in some 
pathophysiological conditions 
(arthritis, SLE, inflammatory bowel 
disease, psoriasis, hepatitis and 
multiple sclerosis)177 
 
RBP Protein produced in the 
liver. 
Filtered through the 
glomeruli; reabsorbed 
and metabolized by the 
renal proximal tubule 
13 
Renal tubular 
dysfunction20 
Urinary levels: yes13 Urine13 ELISA; 
Nephelometric assay14 
Drug-induced 
nephrotoxicity154,178 
Neonates following birth 
asphyxia179 
Stable in acid urine13,20 Saturation of tubular reabsorption 
can be limited its detection20 
Heavy glomerular proteinuria or 
high filtration state may be 
influenced the RBP specificity as an 
AKI biomarker20 
 
β2M Light chain component 
of the major 
histocompatibility 
class I molecule. 
Filtered through the 
glomeruli; absorbed 
and metabolized by the 
renal proximal 
tubule180 
 
Toxic 
injury178 
Serum levels: 2 (0.6 
-2.8) mg/L 
 
Urinary levels: 80 
(3.6 - 320) µg/L181 
Urine178 ELISA; 
Nephelometric assay14 
Drug-induced 
nephrotoxicity154,178 
 
 
 
 
     ______________ 
Unstable in acid urine178 
Levels β2M may be influenced by 
decrease of GFR178 
IGFBP7 
and TIMP2 
IGFBP7: secreted 
protein; TIMP2: 
protein, apparently, 
synthesized by renal 
tubular cells149 
 
Sepsis182 or 
ischemic 
injury183 
Urinary levels: yes149 Urine149 ELISA; Fluorescence 
immunoassay149 
Critically ill adult patients in 
ICU149 
Adult184 and children185 
undergoing cardiac surgery  
As predictor of AKI, 
was superior to other 
biomarkers149 
Lack studies about their 
pathophysiology19 
MicroRNA Small and noncoding 
sequences of RNA186 
Ischemic or 
toxic injury186 
Serum and urinary 
levels: yes187 
Urine/ 
Serum187 
Real-time PCR186 CIN188 
Adult undergoing cardiac 
surgery187 
High stability, non-
invasive, simple, 
sensitive186 
 
Need more clinical studies189 
 
Table I. Novel biomarkers of acute kidney injury. Abbreviations: AKI: Acute Kidney Injury; CIN: Contrast-induced nephropathy; CysC: Cystatin C; DGF: Delay graft function; 
ED: Emergency department; ELISA: Conventional enzyme-linked immunosorbent assay; GFR: Glomerular Filtration Rate; ICU: Intensive Care Unit; IGFBP7: Insulin-like 
Growth Factor-Binding Protein 7; IL-18: Interleukin-18; KIM-1: Kidney Injury Molecule 1; L-FABP: Liver-type Fatty Acid-Binding protein; NAG: N-Acetyl-β-D-
glucosaminidase; PCR: Polymerase Chain Reaction; RBP: Retinol-Binding Protein; RNA: Ribonucleic Acid; SLE: Systemic Lupus Erythematosus; TIMP2: Tissue Inhibitor of 
Metalloproteinases-2; β2M: β2-Microblobulin 
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Appendix II – Table II 
 
Author Study type Sample Size 
(AKI/ no AKI) 
Population 
type 
Clinical setting NGAL 
mesurement 
Method of detection AUC for AKI 
prediction 
AKI definition Prognostic outcome 
Mishra et al., 200529 Prospective 71 
(20/51) 
Children After cardiac surgery Urine ELISA 0.998 ≥ 50% increase in sCr 
concentration from baseline 
 
Plasma ELISA 0.906 
Bachorzewska-
Gajewska et al., 200668 
Prospective 35 Adults CIN Urine ELISA Not reported ____  
Plasma ELISA Not reported 
Mishra et al., 2006124 Prospective 25 Children DGF following 
kidney 
transplantation 
Biopsies NGAL staining Not reported DGF:  need for dialysis within the 
first week after transplantation. 
 
Parikh et al., 2006121 Prospective 53 Adults and  
children 
DGF following 
kidney 
transplantation 
Urine ELISA 0.900 DGF:  need for dialysis within the 
first week after transplantation. 
 
Wagener et al., 200639 Prospective 81 
(16/65) 
Adults After cardiac surgery Urine ELISA 0.800 ≥ 50% increase in sCr 
concentration compared with 
preoperative 
 
Dent et al., 200742 Prospective 120 
(45/75) 
Children After cardiac surgery Plasma Triage Meter 0.960 RIFLE criteria Prediction of length of stay and 
mortality 
Hirsch et al., 200766 Prospective 91 
(11/80) 
Children CIN Urine ELISA 0.920 50% increase in sCr concentration 
from baseline 
 
Plasma ELISA 0.910 
Zappitelli et al., 200778 Prospective 140 
 
Children Critically ill patients 
admitted to the ICU 
Urine ELISA 0.780 Pediatric RIFLE criteria  
Bennett et al., 200837 Prospective 196 
(99/97) 
Children After cardiac surgery Urine CMIA 0.950 ≥ 50% increase in sCr 
concentration from baseline 
Prediction of length of stay, 
worsening AKI, need for RRT 
and mortality 
Koyner et al., 200847 Prospective 72 
(34/38) 
Adults After cardiac surgery Urine 
 
ELISA 
 
0.710 Increase in  sCr ≥ 25% or RRT 
within first 72h 
 
Ling et al., 200867 Prospective 150 
(13/27) 
Adults CIN Urine ELISA 0.734 Increase in sCr ≥ 44.2 µmol/l or ≥ 
25 % from baseline 48 – 72h after 
the procedure 
 
Nickolas et al., 200833 Prospective 635 
 
Adults Patients admitted to 
the ED 
Urine Immunoblot 0.948 RIFLE criteria Prediction of need for RRT  
Vaidya et al., 2008107 Prospective 204 
(102/102) 
Adults Patients admitted to 
the ED 
Urine Microbead based 
assays 
0.890 RIFLE criteria  
Wagener et al., 200840 Prospective 426 
(85/341) 
Adults After cardiac surgery Urine ELISA 0.611 Increase in sCr > 0.3 mg/dL or 
50% from baseline 48 h after the 
surgery 
 
Wheeler et al., 200888 Prospective 143 
(22/121) 
Children Patients with septic 
shock admitted to the 
ICU 
Plasma ELISA 0.677 sCr > 2 mg/dL; BUN > 100 mg/dL 
OR need for RRT 
 
Xin et al., 200852 Prospective 33 
(9/24) 
Adults After cardiac surgery Urine ELISA 0.883 Increase in sCr ≥ 50% within 48 h 
OR UOP < 0.5 mL/kg/hr for > 6h 
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Bachorzewska-
Gajewska et al., 200969 
Prospective 25 Adults CIN Urine ELISA Not reported ____  
Plasma ELISA Not reported 
Haase-Fielitz et al., 
200935 
Prospective 100 
(23/77) 
 
Adults After cardiac surgery Plasma Triage Meter 0.870 > 50% in creatinine baseline to 
peak value within the first five 
postoperative days 
Prediction of length of stay and 
mortality 
Han et al., 200963 Prospective 90 
(36/54) 
Adults After cardiac surgery Urine 
 
ELISA 
 
0.650 >0.3 mg/dL or 2-3-fold creatinine 
rise within first 72h 
 
Lebkowska et al., 
2009190 
Prospective 41 Adults DGF following 
kidney 
transplantation 
Plasma ELISA 0.990 DGF:  need for dialysis within the 
first week after transplantation. 
 
Liangos et al., 200964 Prospective 103 
(13/90) 
Adults After cardiac surgery Urine Immunoassay 0.500 ≥50% creatinine rise within first 
72h 
 
Makris et al., 200979 Prospective 31 
(11/20) 
Adults Multi-trauma patient 
admitted to the ICU 
Urine ELISA 0.977 RIFLE criteria  
Niemann et al., 2009114 Prospective 59 
(27/32) 
Adults After liver 
transplantation 
Plasma ELISA 0.790 RIFLE criteria  
Siew et al., 200983 Prospective 391 
(86/305) 
Adults Critically ill patients 
admitted to the ICU 
Urine ELISA 0.710 AKIN criteria  
Tuladhar et al., 200941 Prospective 50 
(9/41) 
Adults After cardiac surgery Urine ELISA 0.960 RIFLE criteria  
Plasma ELISA 0.850 
Che et al., 2010 48 Retrospective 29 
(14/15) 
Adults After cardiac surgery Urine ELISA 0.850 RIFLE criteria  
Constantin et al., 
201084 
Prospective 88 
(45/43) 
Adults Critically ill patients 
admitted to the ICU 
Plasma Triage Meter 0.920 RIFLE criteria  
Cruz et al., 201092 Prospective 301 
(133/168) 
Adults Critically ill patients 
admitted to the ICU 
Plasma Triage Meter 0.780 RIFLE criteria Prediction of worsening AKI, 
need for RRT and mortality 
Gaspari et al., 2010102 Prospective 46 
(12/12) 
Adults Cisplatin-associated 
nephrotoxicity 
Urine ELISA Not reported > 25% increase in sCr 
concentration from baseline 
 
Plasma ELISA Not reported 
Hall et al., 2010122 Prospective 91 
(34/57) 
Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.780 DGF:  need for dialysis within the 
first week after transplantation. 
Prediction of need for RRT 
Koyner et al., 201034 Prospective 123 
(46/77) 
Adults After cardiac surgery Urine ELISA 0.880 AKIN criteria  
Martensson et al., 
201080 
Prospective 65 
(31/34) 
Adults Patients with septic 
shock admitted to the 
ICU 
Urine RIA 0.860 AKIN and RIFLE criteria  
Plasma RIA 0.670 
Perry et al., 201046 Retrospective 879 
(75/804) 
Adults After cardiac surgery Plasma Triage Meter 0.754 ≥ 50% increase in sCr 
concentration from baseline 
 
Portal et al., 2010117 Prospective 80 
(30/50) 
Adults After liver 
transplantation 
Plasma ELISA 0.870 AKIN criteria  
Prabhu et al., 201056 Prospective 30 
(8/22) 
Adults After cardiac surgery Plasma ELISA 0.980 RIFLE criteria  
Shaker et al., 201070 Prospective 30 Adults CIN Plasma ELISA Not reported   
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Shapiro et al., 2010109 Prospective 661 Adults Patients admitted to 
the ED 
Plasma Triage Meter 0.820 > 0.5 mg /dL increase in sCr OR 
need for RRT within 72h 
 
de Geus et al., 201181 Prospective 632 
(171/461) 
Adults Critically ill patients 
admitted to the ICU 
Urine Triage Meter 0.850 RIFLE criteria Prediction of need for RRT and 
mortality Plasma Triage Meter 0.800 
de Geus et al., 201182 Prospective 510 
(66/444) 
Adults Critically ill patients 
admitted to the ICU 
Urine Triage Meter 0.800 RIFLE criteria  
Plasma Triage Meter 0.760 
Du et al., 2011106 Prospective 252 Children Patients admitted to 
the ED 
Urine ELISA 0.800 Pediatric RIFLE criteria  
Endre et al., 201193 Prospective 528 Adults Critically ill patients 
admitted to the ICU 
Urine ELISA 0.850 AKIN and RIFLE criteria Prediction of worsening AKI, 
need for RRT and mortality 
Krawczeski et al., 
201136 
Prospective 38 
(8/27) 
Neonates After cardiac surgery Urine ELISA 0.950 AKIN criteria  
Plasma ELISA 0.950 
Krawczeski et al., 
201150 
Prospective 220 
(60/160) 
Children After cardiac surgery Urine ELISA 0.900 ≥ 50% in creatinine baseline 
within the first two postoperative 
days 
Prediction of length of stay. 
Heise et al., 201149 Prospective 50 Adults After cardiac surgery Urine ELISA 0.733 AKIN criteria  
Hollmen et al., 2011125 Prospective 176 Adults DGF following 
kidney 
transplantation 
Urine CMIA 0.748 DGF:  need for dialysis within the 
first week after transplantation. 
 
Hollmen et al., 2011126 Prospective 275 Adults DGF following 
kidney 
transplantation 
Urine CMIA 0.595 DGF:  need for dialysis within the 
first week after transplantation. 
 
Plasma ELISA Not reported 
Parikh et al., 201130 Prospective 1219 
(60/1159) 
Adults After cardiac surgery Urine CMIA 0.670 AKIN and RIFLE criteria Prediction of length of stay and 
mortality Plasma Triage Meter 0.700 
Parikh et al., 201165 Prospective 311 
(53/258) 
Children After cardiac surgery Urine CMIA 0.710 AKIN and RIFLE criteria Prediction of length of stay and 
need for RRT Plasma Triage Meter 0.560 
Singer et al., 201132 Prospective 145 Adults Patients admitted to 
the ED 
Urine CMIA 0.870 RIFLE criteria Prediction of worsening AKI, 
need for RRT and mortality 
Wagener et al., 2011119 Prospective 92 Adults After liver 
transplantation 
Urine ELISA 0.800 RIFLE criteria  
Cheng et al., 2012115 Prospective 26 
(13/13) 
Adults After liver 
transplantation 
Plasma ELISA 0.781 AKIN criteria  
Fadel et al., 201243 Prospective 40 
 
Children After cardiac surgery Plasma ELISA Not reported Pediatric RIFLE criteria  
Heyne et al., 2012128 Prospective 182 Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.980 DGF:  need for dialysis within the 
first week after transplantation 
 
Lee et al.,2012129 Retrospective 59 Adults DGF following 
kidney 
transplantation 
Plasma ELISA 0.860 DGF:  need for dialysis within the 
first week after transplantation 
 
Li et al., 2012113 Prospective 25 
(11/14) 
Adults After liver 
transplantation 
Urine ELISA 0.773 AKIN criteria  
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Magnusson et al., 
2012127 
Prospective 111 Adults DGF following 
kidney 
transplantation 
Plasma ELISA Not reported DGF:  need for dialysis within the 
first week after transplantation 
 
Nickolas et al., 2012105 Prospective 1635 Adults Patients admitted to 
the ED 
Urine CMIA 0.810 RIFLE criteria Prediction of need for RRT and 
mortality 
Rahimzadeh et al., 
2012130 
Prospective 27 Children DGF following 
kidney 
transplantation 
Urine ELISA Not reported DGF:  need for dialysis within the 
first week after transplantation 
 
Plasma ELISA 0.950 
Royakkers et al., 
201286 
Prospective 140 Adults Critically ill patients 
admitted to the ICU 
Urine ELISA 0.480 RIFLE criteria  
Plasma ELISA 0.530 
Salamzadeh et al., 
2012139 
Prospective 68 
(11/57) 
Adults DGF following 
kidney 
transplantation 
Urine ELISA Not reported DGF:  need for dialysis within the 
first week after transplantation 
 
Aydogdu et al., 201385 Prospective 151 Adults Patients with sepsis 
admitted to the ICU 
Urine ELISA 0.800 RIFLE criteria  
Plasma ELISA 0.440 
Cho et al., 201387 Prospective 145 
(54/91) 
Adults Critically ill patients 
admitted to the ICU 
Urine ELISA 0.773 AKIN criteria  
Choi et al., 2013135 Prospective 69 Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.778 DGF:  need for dialysis within the 
first week after transplantation 
 
Dedeoglu et al., 
2013116 
Prospective 26 
(9/17) 
Adults After liver 
transplantation 
Urine Triage Meter 0.800 AKIN criteria  
Plasma Triage Meter 0.860 
Fonseca et al., 2013136 Prospective 40 
(18/22) 
Adults DGF following 
kidney 
transplantation 
Urine CMIA 0.990 DGF:  need for dialysis within the 
first week after transplantation 
 
Hong et al., 201395 Prospective 45 
(11/34) 
Adults Burned Plasma Triage Meter 0.903 RIFLE criteria  
Khosravi et al., 2013120 Prospective 90 
(31/59) 
Adults After liver 
transplantation 
Plasma ELISA 0.640 ≥ 0.3 mg/dL in creatinine baseline 
within the first two postoperative 
days 
 
Liebetrau et al., 201354 Prospective 141 
(47/94) 
Adults After cardiac surgery Urine CMIA 0.900 KDIGO criteria  
Lin et al., 2013104 Prospective 33 
(10/23) 
Adults Cisplatin-associated 
nephrotoxicity 
Urine ELISA 0.865 ____  
Liu et al., 201355 Prospective 109 
(26/83) 
Adults After cardiac surgery Urine ELISA 0.871 AKIN criteria  
Peco-Antic et al., 
201353 
Prospective 112 
(18/94) 
Children After cardiac surgery Urine ELISA 0.930 > 25% decrease in estimated 
creatinine clearance at 48h after 
surgery 
 
Plasma ELISA 0.450 
Pickering et al., 201389 Prospective 528 Adults Critically ill patients 
admitted to the ICU 
Plasma Triage Meter 0.790 RIFLE criteria Prediction of need for RRT 
Rostami et al., 2013131 Prospective 64 Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.713 DGF:  need for dialysis within the 
first week after transplantation 
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Schinstock et al., 
2013108 
Prospective 363 Adults Patients admitted to 
the ED 
Urine ELISA 0.700 AKIN criteria  
Sirota et al., 2013118 Prospective 40 
(7/33) 
Adults After liver 
transplantation 
Urine ELISA 0.833 RIFLE and AKIN criteria  
Soto et al., 2013111 Prospective 616 Adults Patients admitted to 
the ED 
Plasma Triage Meter 0.890 AKIN and RIFLE criteria  
Valette et al., 201372 Prospective 98 
(30/68) 
Adults CIN Plasma Triage Meter 0.610 AKIN criteria Prediction of need for RRT 
Zheng et al., 201359 Prospective 58 
(29/29) 
Children After cardiac surgery Urine ELISA 0.859 AKIN criteria  
Alcaraz et al., 201457 Prospective 106 
(36/70) 
Children After cardiac surgery Urine CMIA 0.860 Pediatric RIFLE criteria  
Buemi et al., 2014134 Prospective 97 Adults DGF following 
kidney 
transplantation 
Urine Sandwich enzyme 
immunoassay and 
Triage Meter 
Not reported DGF:  need for dialysis within the 
first week after transplantation 
 
Plasma Sandwich enzyme 
immunoassay and 
Triage Meter 
0.850 
Hollmen et al., 2014141 Prospective 176 Adults DGF following 
kidney 
transplantation 
Plasma ELISA and Triage 
Meter 
0.853 DGF:  need for dialysis within the 
first week after transplantation 
 
Kidher et al., 201444 Prospective 53 
(16/37) 
Adults After cardiac surgery Plasma Triage Meter 0.830 RIFLE criteria  
Kim et al., 201445 Retrospective 37 
(6/31) 
Adults After cardiac surgery Plasma Triage Meter Not reported AKIN criteria  
Liebetrau et al., 201473 Prospective 128 
(14/114) 
Adults CIN Urine CMIA 0.939 KDIGO criteria  
Padhy et al., 201474 Prospective 250 
(30/220) 
Adults CIN Plasma ELISA 1.000 ≥ 0.5 mg/dL in creatinine baseline 
within the first 48h 
 
Pajek et al., 2014138 Prospective 71 Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.820 DGF:  need for dialysis within the 
first week after transplantation 
 
Qurashi et al., 2014140 Prospective 67 Adults DGF following 
kidney 
transplantation 
Urine CMIA Not reported DGF:  need for dialysis within the 
first week after transplantation 
 
Tsuchimoto et al., 
2014103 
Prospective 93 
 
Adults Tacrolimus-
associated 
nephrotoxicity 
Urine ELISA 0.876 AKIN criteria  
Yavuz et al., 201498 Prospective 22 
(6/16) 
Children Burned Urine ELISA 0.960 RIFLE criteria  
Plasma ELISA 0.940 
Zeng et al., 201458 Prospective 197 
(37/160) 
Adults After cardiac surgery Urine ELISA 0.830 AKIN criteria  
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Cantaluppi et al., 
2015132 
Prospective 50 
(14/36) 
Adults DGF following 
kidney 
transplantation 
Plasma Triage Meter 0.940 DGF:  need for dialysis within 
the first week after transplantation 
 
Lichosik et al., 201576 Prospective 33 Children CIN Urine ELISA 0.998 Pediatric RIFLE criteria  
Plasma ELISA 0.910 
Pianta et al., 2015137 Prospective 81 Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.770 DGF:  need for dialysis within 
the first week after transplantation 
 
Quintavalle et al., 
201577 
Prospective 458 
(64/394) 
Adults CIN Urine CMIA 0.610 ≥ 0.3 mg/dL in creatinine baseline 
within the first 48h 
Prediction of need for RRT and 
mortality Plasma ELISA 0.620 
Seker et al., 2015100 Prospective 42 Adults Platin-associated 
nephrotoxicity 
Urine CMIA Not reported ____  
Sen et al., 201594 Prospective 30 
(14/16) 
Adults Burned Plasma Triage Meter 0.820 RIFLE criteria  
Shahbazi et al., 2015101 Prospective 24 
(2/22) 
Adults Cisplatin-associated 
nephrotoxicity 
Urine ____ 0.800 AKIN criteria  
Surmiak et al., 2015112 Prospective 21 
(8/13) 
Neonates HLHS Plasma Sandwich enzyme 
immunoassay 
0.920 AKIN criteria  
Taghizadeh-Ghehi et 
al., 201599 
Prospective 72 
(12/60) 
Adults After HSCT Urine ELISA 0.860 RIFLE and AKIN criteria  
Benzer et al., 201675 Prospective 141 
(91/50) 
Children CIN Plasma Sandwich enzyme 
immunoassay 
Not reported Pediatric RIFLE criteria  
Fanning et al., 201651 Prospective 50 
(31/19) 
Adults After cardiac 
surgery 
Urine ELISA 0.712 KDIGO criteria  
Huang et al., 201690 Prospective 76 
(30/46) 
Adults Patients with sepsis 
admitted to the ICU 
Plasma ELISA 0.731 RIFLE criteria  
Kamis et al., 201691 Prospective 107 
(38/69) 
Adults Critically ill patients 
admitted to the ICU 
Urine ELISA 0.930 RIFLE criteria  
Plasma ELISA 1.000 
Lacquaniti et al.,    
2016133 
Prospective 29 
(22/7) 
Adults DGF following 
kidney 
transplantation 
Urine ELISA 0.979 DGF:  need for dialysis within 
the first week after transplantation 
 
Plasma ELISA 0.670 
Moriyama et al., 
201662 
Prospective 50 
(11/39) 
Adults After cardiac 
surgery 
Urine ELISA 0.869 KDIGO criteria  
Rakkolainen et al., 
201697                      
Prospective 19 
(9/10) 
Adults Burned Plasma Triage Meter 0.623 AKIN criteria  
Chun et al., 201796 Prospective 76 Adults Burned Plasma Triage Meter 0.679 AKIN criteria Prediction of need for RRT and 
mortality 
Dong et al., 201760 Prospective 150 
(50/100) 
Children After cardiac 
surgery 
Urine ELISA >0.900 KDIGO criteria  
Hang et al., 2017110 Prospective 249 Adults Patients admitted to 
the ED 
Plasma Triage Meter 0.923 Increase in sCr ≥ 0.3mg/dL (26.5 
mmol/L) within 48 h; increase 1.5 
times in creatinine baseline within 
the prior 7 days OR UOP < 0.5 
ml/kg/h for 6 h. 
Prediction of mortality. 
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Table II. Performance of Neutrophil Gelatinase-Associated Lipocalin in clinical studies. Abbreviations: AKIN: Acute Kidney Injury Network criteria; AUC: area under the 
receiver operator characteristic curve; BUN: blood urea nitrogen; CIN: Contrast-induced nephropathy; CMIA: chemiluminescent microparticle immunoassay; DGF: Delay graft 
function; ED: Emergency department; ELISA: Conventional enzyme-linked immunosorbent assay; HLHS: hypoplastic left heart syndrome; HSCT: hematopoietic stem cell 
transplantation; ICU: intensive care unit; NGAL: Neutrophil Gelatinase-Associated Lipocalin; RIA: polyclonal antibody based radioimmunoassay; RIFLE: Risk, Injury, Failure, 
Loss and End-stage Kidney criteria; RRT: renal replacement therapy; sCr: serum creatinine; UOP: urine output. 
 
 
 
Kalisnik et al., 201761 Prospective 41 
(18/23) 
Adults After cardiac 
surgery 
Plasma ELISA 0.669 ≥ 150% in creatinine baseline OR 
> 26.4 mmol/L within the first 
two postoperative days 
 
Ribitsch et al., 201771 Prospective 617 
(58/559) 
Adults CIN Urine CMIA 0.510 RIFLE criteria  
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Appendix III – Figure 1 
 
 
 
Figure 1. Clinical setting. Abbreviations: CIN: Contrast-induced nephropathy; CS: After cardiac surgery; 
DGF: Delay graft function following kidney transplantation; ED: patients admitted to the Emergency 
department; ICU: patients admitted to the intensive care unit; LT: After liver transplantation; NT: drug-
associated nephrotoxicity. 
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Appendix IV – Table III 
 
Clinical setting Clinical studies number AUC 
Urine Plasma Urine / Plasma Urine 
Mean (SD) 
Plasma 
Mean (SD) 
Total 
Mean (SD) 
After cardiac surgery 19 8 6 0.816 (0.13) 0.790 (0.17) 0.807 (0.14) 
DGF following kidney transplantation 11 5 4 0.823 (0.13) 0.873 (0.11) 0.843 (0.12) 
Patients admitted to the ICU 5 5 6 0.800 (0.13) 0.736 (0.16) 0.769 (0.15) 
CIN 3 4 5 0.785 (0.20) 0.810 (0.18) 0.797 (0.18) 
Patients admitted to the ED 6 3 0 0.836 (0.09) 0.878 (0.05) 0.850 (0.08) 
After liver transplantation 3 4 1 0.802 (0.02) 0.788 (0.09) 0.794 (0.07) 
Drug-associated nephrotoxicity  4 0 1 0.847 (0.04) - 0.847 (0.04) 
Burned 0 4 1 - 0.793 (0.14) 0.821 (0.14) 
Table III. Clinical studies analyses. Abbreviations: AUC: area under the receiver operator characteristic 
curve; CIN: Contrast-induced nephropathy; DGF: Delay graft function; ED: Emergency department; ICU: 
intensive care unit; SD: Standard Deviation. 
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Appendix V - Portuguese Journal of Nephrology and Hypertension: 
Instructions to Authors 
 
AIMS AND SCOPE 
The Portuguese Journal of Nephrology and Hypertension is the official organ of the 
Portuguese Society of Nephrology and is published quarterly. Supplementary issues are 
also published including selected themes, at the discretion of the Editor-in-Chief, as well 
as abstracts of the annual congresses of the Society. The Journal is peer-reviewed and is 
indexed in Thompson Reuter’s SciELO Citation Index, with free online access in our 
website http://www.spnefro.pt/RPNH. 
The Journal publishes articles on clinical or laboratory topics of relevance to nephrology, 
dialysis, transplantation and hypertension. Papers relating to basic immunology, 
physiology, genetics and epidemiology are accepted when kidney-related. Manuscripts 
must be submitted in English to the Editor-in-Chief. Only previously unpublished work 
should be submitted. The Editor-in-Chief has complete editorial freedom. 
The Journal complies with the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals produced by the ICMJE (International Committee of Medical 
Journal Editors). 
Visit http://www.icmje.org 
 
REVIEW AND PUBLICATION SPEED 
All submissions will be subject to an immediate editorial screening process by the Editor-
in-Chief after which they will normally be sent to two or three reviewers. The Editor-in-
Chief will make every effort to reach a decision on all submitted papers within 8 weeks 
of receipt. Papers will normally be published in the next issue to go to press after their 
acceptance. Papers that do not meet the scientific standards of the Journal may be declined 
by the Editor-in-Chief without further review. 
 
CONTENT TYPES 
The Portuguese Journal of Nephrology and Hypertension publishes: 1) Editorials; 2) 
Review Articles; 3) Original Articles; 4) Case Reports; 5) Letters to the Editor; 6) 
Nephropathology Quiz; 7) Perspective; 8) Comments. 
Editorials 
Editorials are usually invited, but authors may propose a paper for the Editor-in-Chief’s 
consideration. They may have up to 2000 words and a maximum of 2 tables or figures. A 
maximum of 5 references is generally recommended. 
Review Articles 
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Review articles should provide novel insights and comprehensive analyses of topics on 
Nephrology, and interpretation of the published literature. They are usually 
commissioned by the Editors. However, unsolicited reviews will be considered. These 
articles may have up to 5000 words and an abstract of up to 300 words. The use of 3 tables 
or figures is acceptable. A maximum of 70 references is generally recommended. 
Original Articles 
An original article must focus on relevant clinical investigation or basic research, and is 
limited to 4000 words including an abstract with up to 300 words. The order of the text 
should be as follows: Introduction, Subjects and Methods (any statistical method must be 
detailed in this section), Results and Discussion. A maximum of 50 references is generally 
recommended. 
Case Reports 
Original and succinct description structured in Introduction, Case Report and Discussion. 
They should not exceed 2500 words (including an abstract up to 300 words) and should 
not include more than 4 tables or figures. A maximum of 30 references is generally 
recommended. 
Letters to the Editor 
Letters must contain information related to an article published in the Journal or may 
concern a topic of current interest in Nephrology. Letters (maximum of 3 authors) are 
limited to 500 words and 1 table or figure. A maximum of 5 references is generally 
recommended. 
Nephropathology Quiz 
A case report to educate clinicians on the renal pathology. This section includes a concise 
clinical history, images of histology and discussion. These articles are usually invited and 
are limited to 2000 words, 8 figures and 20 references. 
Perspective 
Perspective articles are brief, accessible pieces covering a wide variety of timely topics 
of relevance to health care and medicine. They are nearly always solicited, although 
unsolicited articles may occasionally be considered. Perspective articles are limited to 
1000 to 1200 words and may include one figure or table. A maximum of 8 references is 
generally recommended. 
Comments 
Comments usually provide commentary and analysis concerning an article in the issue of 
the Journal in which they appear. They may also provide commentary concerning an 
article published elsewhere. They may include 1 figure or table. They are nearly always 
solicited, although unsolicited comments may occasionally be considered. Comments are 
usually limited to 1000 words, with up to 10 references. 
 
47 
 
INSTRUCTIONS FOR AUTHORS 
Manuscripts must be submitted online http://rpnh.spnefro.pt. Once you have prepared 
your manuscript according to the Instructions below, please pay particular attention to the 
sections on Informed Consent and Ethics and Disclosure. 
 
The text should be double-spaced. The corresponding author should describe the 
contributions of all authors to the article. Manuscripts should bear the name, address and 
e-mail of the corresponding author. 
 
Should the manuscript be accepted for publication the authors will be asked to give signed 
consent for publication in a letter which must contain the statement that “the results 
presented in this paper have not been published previously, in whole or in part, except in 
abstract form”. 
 
Title Page: The title page should carry the full title of the paper and the first name, middle 
initial (if applicable) and last name of each author, plus the names and addresses of the 
respective institutions where the work was done; in the case of different institutions the 
author(s) should be identified using superscript Arabic numerals. 
 
Abstract: Not more than 300 words. Abbreviations should not be used. 
 
Key-Words: Not more than 6, in alphabetical order, and the terms used (when possible) 
should be from the Medical Subject Headings list of the Index Medicus. 
 
References: Authors are responsible for bibliographic accuracy. All the references, 
including those with only electronic sources, should be cited according to the “Vancouver 
Citation Style” which can be consulted on the Internet 
at: http://library.vcc.ca/downloads/VCC_VancouverStyleGuide.pdf 
 
References must be numbered consecutively in the order in which they are cited in the 
text. Each reference should give the name and initials of all authors unless they are more 
than six, when only the first three should be given followed by et al. Authors’ names 
should be followed by the title of the article, journal abbreviations according to the style 
used in Index Medicus, the year of publication, the volume number and the first and last 
page numbers. For papers in the course of publication, “in press” replaces the date; the 
journal name must be given in the references. Manuscripts that are unpublished, in 
preparation, or submitted, and personal communications should not be cited in the 
reference list but may appear parenthetically in the text. References to books should 
contain the author(s) name(s) and initials, the title of the book, followed by place of 
publication, publisher, year, and relevant pages. Websites must be referenced by the 
following order: title, URL and access date. 
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Examples 
 
1. Journals: 
Hogan J, Mohan P, Appel GB. Diagnostic tests and treatment options in glomerular 
disease: 2014 update. Am J Kidney 
Dis 2014;63(4):656-666 
 
2. Books: 
Morris Peter, Knechtle Stuart. Kidney Transplantation - Principles and Practice. 7th 
Edition. Saunders, 2014:72 
 
3. Website: 
Substitutive Renal Therapy of Chronic Renal Disease in Portugal.  
Available at http:www.spnefro.pt/comissoes_Gabinete_registo_2013/registo_2013. 
Accessed October 6, 2013. 
 
4. Published Meeting Abstract: 
Jorge Silva, Jorge Antunes, Telmo Carvalho, Pedro Ponce. 
Efficacy of preventing hemodialysis catheter infections with citrate lock (Encontro Renal 
abstract SE001). Port J Nephrol Hypert 2011; 25(1):56 
 
Tables: Tables should supplement, not duplicate, the information in the main text. 
References to tables should be made in order of appearance in the text and should be in 
Roman numerals in brackets, e.g. (Table II). Each table should be typed on a separate 
sheet and have a brief heading describing its contents. 
 
Figures: All illustrations (transparencies, photographs, diagrams, graphs, etc.) should be 
labelled consecutively in Arabic numerals (Fig. 1, 2...), according to their relative 
positions in the text. If a figure has been published before, the original source must be 
acknowledged and written permission from the copyright holder must be submitted with 
the material. 
 
Informed Consent and Ethics: Identifying details of patients should not be published in 
descriptions unless the information is essential for scientific purposes and the patient 
gives written informed consent for publication. Patients shown in photographs should 
have their identity obscured or the picture must be accompanied by written permission to 
use the photograph. 
 
When reporting experiments on human subjects, it is mandatory to indicate whether the 
procedures were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and with the Helsinki Declaration 
of 1975 (revised in 2015) and, in the case of renal transplant, the Declaration of Istanbul. 
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When reporting experiments on animals, authors should indicate whether the institutional 
and national guide for the care and use of laboratory animals was followed. 
 
Disclosure: Each manuscript must include a conflict of interest statement before the 
References section. The disclosure statement will describe the sources of any support for 
the work in the form of grants, consulting fees or honoraria from industry, equipment, 
provision of drugs, travel related with the study or any combination thereof. Any relevant 
financial activities outside the submitted paper but considered stakeholders in the field 
must be detailed. The corresponding author should provide a Conflict of Interest 
Declaration describing the possible financial interests of all the authors. The absence of 
any interest must also be declared. 
 
Acknowledgements should be located in the manuscript body before the conflict of 
interest statement. 
 
